Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179663896> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3179663896 abstract "Background: ATR is an essential regulator of DNA damage response in cancers. However, the expression and significance of ATR in osteosarcoma is poorly defined. In this study, we evaluated the clinical value and analyzed the mechanism of ATR selective targeting in metastatic osteosarcoma. Methods: Immunohistochemistry was performed on osteosarcoma tissue microarrays constructed from 70 patient specimens to quantify ATR and activated pATR expression and its possible correlation with clinical outcomes. Sublocation in metastatic osteosarcoma cells was confirmed by immunofluorescence assay. Cell proliferation, apoptosis and migration were evaluated under circumstances of treatment with siRNA or inhibitor Berzosertib. Antitumor activity were determined by ex vivo 3D culture models. Effects on cell cycle and DNA damage repair pathways were detected by Western blotting. Findings: Elevated ATR and activated pATR expression correlate with worse patient survival and less necrosis following neoadjuvant chemotherapy. Intranuclear sublocalization of ATR and pATR suggested a relation to DNA replication. Knockdown with siRNA or inhibition with Berzosertib suppressed cell growth and proliferation in a time- and dose-dependent manner while induced apoptosis. In addition, ATR inhibition decreased Chk1 phosphorylation while increased γH2AX expression and PARP cleavage, consistent with interference in both G2-M checkpoint regulation and DNA damage repair. Of note, the ATR inhibitor Berzosertib produced a characteristic cytoplasmic vacuolization that precedes cell death in osteosarcoma cells. ATR inhibition also suppressed ex vivo 3D spheroid formation and cell motility. Interpretation: The faithful dependence of cells on ATR signaling for survival and progression makes it a potential novel treatment modality for metastatic osteosarcoma.Funding Statement: This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-1- 005), the Capital characterized clinical application research Fund of Beijing Municipal Science &Technology Commission of China (Z171100001017210), Beijing Hope Run Special Fund of Cancer Foundation of China (LC2016L01), a Grant from Sarcoma Foundation of America (SFA) (222433) and a Grant from National Cancer Institute (NCI)/National Institutes of Health (NIH) (UO1, CA151452-01). Declaration of Interests: The authors declare no potential conflicts of interest need to be disclosed.Ethics Approval Statement: The study was approved by the Partners Human Research Committee (#: 2007P-002464) and all patients signed a consent form for their clinical information to be used for this research." @default.
- W3179663896 created "2021-07-19" @default.
- W3179663896 creator A5003674196 @default.
- W3179663896 creator A5009665768 @default.
- W3179663896 creator A5026961383 @default.
- W3179663896 creator A5033769845 @default.
- W3179663896 creator A5038077156 @default.
- W3179663896 creator A5050384951 @default.
- W3179663896 creator A5055817420 @default.
- W3179663896 date "2020-01-01" @default.
- W3179663896 modified "2023-10-14" @default.
- W3179663896 title "ATR Expression as a Prognostic Biomarker and Therapeutic Target in Metastatic Osteosarcoma" @default.
- W3179663896 doi "https://doi.org/10.2139/ssrn.3572848" @default.
- W3179663896 hasPublicationYear "2020" @default.
- W3179663896 type Work @default.
- W3179663896 sameAs 3179663896 @default.
- W3179663896 citedByCount "0" @default.
- W3179663896 crossrefType "journal-article" @default.
- W3179663896 hasAuthorship W3179663896A5003674196 @default.
- W3179663896 hasAuthorship W3179663896A5009665768 @default.
- W3179663896 hasAuthorship W3179663896A5026961383 @default.
- W3179663896 hasAuthorship W3179663896A5033769845 @default.
- W3179663896 hasAuthorship W3179663896A5038077156 @default.
- W3179663896 hasAuthorship W3179663896A5050384951 @default.
- W3179663896 hasAuthorship W3179663896A5055817420 @default.
- W3179663896 hasConcept C105696609 @default.
- W3179663896 hasConcept C134935766 @default.
- W3179663896 hasConcept C142724271 @default.
- W3179663896 hasConcept C143425029 @default.
- W3179663896 hasConcept C173396325 @default.
- W3179663896 hasConcept C190283241 @default.
- W3179663896 hasConcept C193270364 @default.
- W3179663896 hasConcept C203014093 @default.
- W3179663896 hasConcept C204232928 @default.
- W3179663896 hasConcept C2777760704 @default.
- W3179663896 hasConcept C29537977 @default.
- W3179663896 hasConcept C50001416 @default.
- W3179663896 hasConcept C502942594 @default.
- W3179663896 hasConcept C54355233 @default.
- W3179663896 hasConcept C552990157 @default.
- W3179663896 hasConcept C55493867 @default.
- W3179663896 hasConcept C62112901 @default.
- W3179663896 hasConcept C71924100 @default.
- W3179663896 hasConcept C86803240 @default.
- W3179663896 hasConceptScore W3179663896C105696609 @default.
- W3179663896 hasConceptScore W3179663896C134935766 @default.
- W3179663896 hasConceptScore W3179663896C142724271 @default.
- W3179663896 hasConceptScore W3179663896C143425029 @default.
- W3179663896 hasConceptScore W3179663896C173396325 @default.
- W3179663896 hasConceptScore W3179663896C190283241 @default.
- W3179663896 hasConceptScore W3179663896C193270364 @default.
- W3179663896 hasConceptScore W3179663896C203014093 @default.
- W3179663896 hasConceptScore W3179663896C204232928 @default.
- W3179663896 hasConceptScore W3179663896C2777760704 @default.
- W3179663896 hasConceptScore W3179663896C29537977 @default.
- W3179663896 hasConceptScore W3179663896C50001416 @default.
- W3179663896 hasConceptScore W3179663896C502942594 @default.
- W3179663896 hasConceptScore W3179663896C54355233 @default.
- W3179663896 hasConceptScore W3179663896C552990157 @default.
- W3179663896 hasConceptScore W3179663896C55493867 @default.
- W3179663896 hasConceptScore W3179663896C62112901 @default.
- W3179663896 hasConceptScore W3179663896C71924100 @default.
- W3179663896 hasConceptScore W3179663896C86803240 @default.
- W3179663896 hasLocation W31796638961 @default.
- W3179663896 hasOpenAccess W3179663896 @default.
- W3179663896 hasPrimaryLocation W31796638961 @default.
- W3179663896 hasRelatedWork W12635241 @default.
- W3179663896 hasRelatedWork W20538935 @default.
- W3179663896 hasRelatedWork W25000151 @default.
- W3179663896 hasRelatedWork W26780953 @default.
- W3179663896 hasRelatedWork W27952881 @default.
- W3179663896 hasRelatedWork W35565299 @default.
- W3179663896 hasRelatedWork W37133419 @default.
- W3179663896 hasRelatedWork W38665066 @default.
- W3179663896 hasRelatedWork W6106852 @default.
- W3179663896 hasRelatedWork W7405620 @default.
- W3179663896 isParatext "false" @default.
- W3179663896 isRetracted "false" @default.
- W3179663896 magId "3179663896" @default.
- W3179663896 workType "article" @default.